Case Report: Bilateral Wilms tumor with TP53 mutation: a case-based review of clinical challenges - Report - MDSpire

Case Report: Bilateral Wilms tumor with TP53 mutation: a case-based review of clinical challenges

  • By

  • Xin Zhang

  • Qianqian Cheng

  • Pinxiu Wang

  • Zhen Tan

  • May 21, 2026

  • 0 min

Share

Clinical Challenges in Managing Bilateral Wilms Tumor with TP53 Mutation

Overview

{'add': 'Include specific treatment protocols and timeline of disease progression.'}

Background

{'add': 'Discuss broader implications of TP53 mutations.'}

Data Highlights

{'add': 'Explain the significance of the absence of numerical data.'}

Key Findings

{'add': 'Ensure findings are supported by case details and include relevant statistics.'}

Clinical Implications

{'add': 'Suggest alternative treatment strategies or research directions.'}

Conclusion

{'add': 'Highlight the need for targeted therapy research for TP53 mutations.'}

Related Resources & Content

  1. Frontiers in Oncology, 2026 -- BRAF V600E-mutated metastatic Wilms tumor with complete response to targeted RAF/MEK inhibition: a post-treatment follow-up case report
  2. Blood Cancer Journal, 2024 -- Factors Influencing Treatment Response and Two-Year Survival in High-Grade Myeloid Neoplasms with TP53 Mutations
  3. The ASCO Post, 2015 -- Expert Point of View: Alison M. Friedmann, MD
  4. The ASCO Post, 2015 -- Intensified Therapy Improves Survival in Wilms Tumor Patients With Rare Genetic Abnormality
  5. Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology - PubMed
  6. Bilateral Wilms tumor with anaplasia: A report from the Children's Oncology Group Study AREN0534 - PubMed
  7. Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology - PubMed
  8. Bilateral Wilms tumor with anaplasia: A report from the Children's Oncology Group Study AREN0534 - PubMed

Original Source(s)

Case Report: Bilateral Wilms tumor with TP53 mutation: a case-based review of clinical challenges

  • by Xin Zhang, Qianqian Cheng, Pinxiu Wang, Zhen Tan

  • May 21, 2026

Related Content

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026